IDH1 and acute myeloid leukemia: In regards to patients not achieving optimal response to HMA-Ven or, in IDH-mutated cases, to IDH inhibitor monotherapy or combination with HMA ± Ven, we favor proceeding with transplant sooner rather than attempting additional salvage therapy in search of CR; in a recent randomized study of patients with relapsed/refractory AML, post-transplant survival was not favorably affected by additional intensive chemotherapy with the objective to attain CR, as opposed to sequential conditioning followed directly by AHSCT [61].